Glenmark Pharmaceuticals has informed about a Press Release dated September 03, 2015 titled ‘Glenmark’s novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe’.
The above information is a part of company’s filings submitted to BSE.